Literature DB >> 14535273

Framing tropical disease in London: Patrick Manson, Filaria perstans, and the Uganda sleeping sickness epidemic, 1891-1902.

D M Haynes1.   

Abstract

Much of the historical literature on tropical medicine represents the periphery as the chief site for the production of western knowledge about disease in the British empire. This study on the Filaria perstans-sleeping sickness hypothesis revises this perspective by showing how the imperial metropole functioned as a culture space for the construction of knowledge about the empire. Beginning in 1891, Patrick Manson used the publicity resources of London to generate a rhetorical imperative for the confirmation of his hypothesis without ever leaving Britain. Later, while he was medical adviser to the imperial state, the 1900 sleeping sickness epidemic in Uganda presented Manson with a unique opportunity to determine the validity of his hypothesis. By exaggerating the possible spread of the epidemic privately among Foreign Office personnel and publicly in the medical press, he succeeded in mobilizing the first Royal Society sleeping sickness research expedition to Africa in 1902. While this expedition ultimately disproved Manson's hypothesis, this outcome ironically created the very conditions for the identification of the actual causal agent (Trypanosoma gambiense) and its vector (tsetse fly) by Aldo Castellani and David Bruce respectively.

Entities:  

Mesh:

Year:  2000        PMID: 14535273     DOI: 10.1093/shm/13.3.467

Source DB:  PubMed          Journal:  Soc Hist Med        ISSN: 0951-631X            Impact factor:   0.973


  2 in total

1.  The nurse of parasites: gender concepts in Patrick Manson's parasitological research.

Authors:  Shang-Jen Li
Journal:  J Hist Biol       Date:  2004       Impact factor: 1.326

Review 2.  In memory of Patrick Manson, founding father of tropical medicine and the discovery of vector-borne infections.

Authors:  Kelvin Kw To; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2012-10-24       Impact factor: 7.163

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.